6 results about "Macrophage migration inhibitory factor" patented technology

Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and / or conditions with the compounds or the composition. The disease states and / or conditions are mediated through MIF / IgG or where MIF / IgG is a contributing factor to the development and perpetuation of diseases and / or conditions, such as autoimmune diseases and cancer, among others.

Provided herein are novel compounds as inhibitors of macrophage migration inhibitory factor (MIF) pharmaceutical compositions comprising the compounds provided herein: as well as uses and methods for treating a disease mediated by MIF by administering the compounds provided herein. In particular, the compounds of the invention may be used as MIF inhibitors.

This invention provides a biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions, its preparation method, and its application. The biomimetic nanoparticle composite PRP hydrogel is formed by cross-linking a hydrogel matrix and composite nanoparticles dispersed therein. The core of the composite nanoparticles is albumin nanoparticles loaded with macrophage migration inhibitory factor inhibitors, and the outer shell of the composite nanoparticles is a fibroblast membrane. The preparation method includes the following steps: preparing a composite nanoparticle dispersion; mixing sodium alginate with the composite nanoparticle dispersion to prepare a sodium alginate solution; adding platelet-rich plasma and mixing evenly; adding calcium carbonate and an acidity regulator; stirring evenly and allowing to stand to form a gel, thus obtaining the biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions.

Provided herein are methods of reducing immune checkpoint therapy resistance, increasing immune checkpoint therapy sensitivity and / or increasing anti-tumor activity in subjects with cancer, methods of treating non-small cell lung cancer (NSCLC), and methods of identifying a subject as a responder to a macrophage migration inhibitory factor (MIF) targeting agent therapy. The methods include identifying alteration in the KEAP1 / NRF2 pathway and administering MIF targeting agent therapy. Illustrative immune checkpoint therapies include PD-1 inhibitors and / or PD-L1 inhibitors.

The present invention relates to a fusion polypeptide derived from Toxoplasma gondii. The fusion polypeptide can be used as a pharmaceutical composition for treating tuberculosis. In particular, the fusion polypeptide according to the present invention acts specifically on the lungs infected with Mycobacterium tuberculosis and has therapeutic efficacy even against tuberculosis having resistance to isoniazid (INH), pyrazinamide (PZA), rifampin (RFP), and / or streptomycin (SM).

The disclosure concerns methods and kits of diagnosis of pancreatic cancer and monitoring disease burden in patients diagnosed with pancreatic cancer, the method comprising quantitative determination of the concentration of extracellular vesicles that are positive for one, two or three markers selected from thrombospondin-2 (THBS2), alkaline phosphatase placental-like 2 (ALPPL2), and macrophage migration inhibitory factor (MIF) in the patients' fluid samples.